Understanding the Therapeutic Potential of Lomecel-B for Alzheimer Disease: Joshua Hare, MD
July 30th 2024The co-founder and chief science officer at Longeveron provided commentary on the therapeutic potential of Lomecel-B, a living cell product in development for patients with Alzheimer disease. [WATCH TIME: 3 minutes]
Expanding the Knowledge Profile and Treatment Capabilities of Lecanemab: Lynn Kramer, MD, FAAN
July 29th 2024The chief medical officer at Eisai provided context towards the ongoing initiatives to further the efficacy and safety profile of lecanemab, an FDA-approved treatment for early Alzheimer disease. [WATCH TIME: 3 minutes]
Transforming the Landscape of Parkinson Disease Care Through Patient-Centric Focus
July 26th 2024Michael Soileau, MD, FAAN, talked about a panel of specialists who discussed the evolution and multidisciplinary treatment of Parkinson disease, emphasizing patient-centered care and advanced therapeutic options.
Advances in Therapeutic Management for Parkinson Disease and Essential Tremor
July 25th 2024Anvi Gadani, MD, assistant clinical professor of medicine at Medstar Georgetown University Hospital, discussed surgical and device-guided therapies for managing advanced Parkinson disease and essential tremor.
Potential of BTK Inhibitors for Primary Progressive Multiple Sclerosis: Patricia K. Coyle, MD
Published: July 23rd 2024 | Updated: June 11th 2024The professor of neurology at Stony Brook Medicine talked about the promising potential in ongoing studies assessing BTK inhibitors as treatment for primary progressive multiple sclerosis. [WATCH TIME: 3 minutes]
Optimizing Localization in Multiple Sclerosis Diagnosis: Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN
July 23rd 2024The assistant professor at Hunter College talked about the approach of localization to prevent misdiagnoses of multiple sclerosis and ensure patients receive appropriate treatment. [WATCH TIME: 3 minutes]
A Comprehensive Program to Enhance Inpatient Care for Patients With Parkinson Disease
Published: July 22nd 2024 | Updated: July 24th 2024Patricia Clark, CNP, a nurse practitioner at the Cleveland Clinic, talked about a specialized program for hospitalized patients with Parkinson disease that aligns hospital protocols with home medication regimens to improve care.
Overviewing the XYLO Study and Low-Sodium Oxybate’s Impact on Blood Pressure: Phil Jochelson, MD
July 12th 2024The therapeutic head for Clinical Development Neuroscience at Jazz Pharmaceuticals provided clinical insight on a new study evaluating the effect of switching from high- to low-sodium oxybate on blood pressure. [WATCH TIME: 4 minutes]
Future Research Efforts in Aging MS
July 11th 2024In the final episode, Negroski gave closing thoughts on some of the major unmet needs in research regarding aging in MS, as well as some of the unanswered questions clinicians are still trying to figure out.
The Importance of Open Communication in Patient Care: Kelly Papesh, DNP, APRN, FNP-BC
July 7th 2024The executive director of the Association of Movement Disorder Advanced Practice Providers discussed how effective patient care in movement disorders can lead to better management and treatment outcomes. [WATCH TIME: 4 minutes]
The Challenges and Innovations in Parkinson Treatment: Michael Soileau, MD, FAAN
July 6th 2024The movement disorder specialist at Texas Movement Disorder Specialists talked about the complexities and advancements in treating Parkinson disease, emphasizing the need for strategic and aggressive treatment approaches despite administrative burdens. [WATCH TIME: 5 minutes]
Cladribine and Other Agents in Aging Multiple Sclerosis
July 3rd 2024Negroski detailed a real-world analysis on cladribine, an FDA-approved DMT, in an aging population of MS, and the recent increase in research for older populations with the disease.